Entrada Therapeutics Q3 net loss widens to $44.1 mln

Reuters11-06

Entrada <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q3 net loss widens to $44.1 mln

Overview

Entrada Therapeutics Q3 net loss widens to $44.1 mln from $14.0 mln last year
Collaboration revenue drops to $1.6 mln from $19.6 mln due to plan completion
Company extends cash runway into Q3 2027 with $327 mln in cash and securities

Outlook

Entrada expects to report ELEVATE-44-201 data in Q2 2026
Company plans to report ELEVATE-45-201 data in mid-2026
Company's cash runway extended into Q3 2027

Result Drivers

DMD PROGRAM COSTS - Increased R&D expenses driven by costs related to DMD programs and higher personnel expenses
COLLABORATION REVENUE DECLINE - Revenue drop attributed to completion of collaboration with Vertex

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Collaboration Revenue		$1.61 mln
Q3 EPS		-$1.06
Q3 Net Income		-$44.13 mln
Q3 Income From Operations		-$47.05 mln
Q3 Operating Expenses		$48.67 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Entrada Therapeutics Inc is $18.50, about 62.5% above its November 5 closing price of $6.94

Press Release: ID:nGNX3s0t0P

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581876067?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581876067","market":"us","top_or_hot":-1,"title":"Entrada Therapeutics Q3 net loss widens to $44.1 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Entrada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss widens to $44.1 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Entrada Therapeutics Q3 net loss widens to $44.1 mln from $14.0 mln last year</p></li><li><p>Collaboration revenue drops to $1.6 mln from $19.6 mln due to plan completion</p></li><li><p>Company extends cash runway into Q3 2027 with $327 mln in cash and securities</p></li></ul><p><span>Outlook</span></p><ul><li><p>Entrada expects to report ELEVATE-44-201 data in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>Company plans to report ELEVATE-45-201 data in mid-2026</p></li><li><p>Company's cash runway extended into Q3 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>DMD PROGRAM COSTS - Increased R&amp;D expenses driven by costs related to DMD programs and higher personnel expenses</p></li><li><p>COLLABORATION REVENUE DECLINE - Revenue drop attributed to completion of collaboration with Vertex</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Collaboration Revenue</p></td><td></td><td><p>$1.61 mln</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$1.06</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$44.13 mln</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$47.05 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$48.67 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Entrada Therapeutics Inc is $18.50, about 62.5% above its November 5 closing price of $6.94</p></li></ul><p>Press Release: <span>ID:nGNX3s0t0P</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Entrada Therapeutics Q3 net loss widens to $44.1 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEntrada Therapeutics Q3 net loss widens to $44.1 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Entrada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss widens to $44.1 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Entrada Therapeutics Q3 net loss widens to $44.1 mln from $14.0 mln last year</p></li><li><p>Collaboration revenue drops to $1.6 mln from $19.6 mln due to plan completion</p></li><li><p>Company extends cash runway into Q3 2027 with $327 mln in cash and securities</p></li></ul><p><span>Outlook</span></p><ul><li><p>Entrada expects to report ELEVATE-44-201 data in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>Company plans to report ELEVATE-45-201 data in mid-2026</p></li><li><p>Company's cash runway extended into Q3 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>DMD PROGRAM COSTS - Increased R&amp;D expenses driven by costs related to DMD programs and higher personnel expenses</p></li><li><p>COLLABORATION REVENUE DECLINE - Revenue drop attributed to completion of collaboration with Vertex</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Collaboration Revenue</p></td><td></td><td><p>$1.61 mln</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$1.06</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$44.13 mln</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$47.05 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$48.67 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Entrada Therapeutics Inc is $18.50, about 62.5% above its November 5 closing price of $6.94</p></li></ul><p>Press Release: <span>ID:nGNX3s0t0P</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TRDA","symbol_name":"Entrada Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0LK:1","article_id":"2581876067","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581876067","pubTimestamp":1762431250,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Entrada Therapeutics Q3 net loss widens to $44.1 mlnOverviewEntrada Therapeutics Q3 net loss widens to $44.1 mln from $14.0 mln last yearCollaboration revenue drops to $1.6 mln from $19.6 mln due to p","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TRDA":"Entrada Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Entrada Therapeutics第三季度净亏损扩大至4410万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRDA":0.9},"content_text":"Entrada Therapeutics Q3 net loss widens to $44.1 mlnOverviewEntrada Therapeutics Q3 net loss widens to $44.1 mln from $14.0 mln last yearCollaboration revenue drops to $1.6 mln from $19.6 mln due to plan completionCompany extends cash runway into Q3 2027 with $327 mln in cash and securitiesOutlookEntrada expects to report ELEVATE-44-201 data in Q2 2026Company plans to report ELEVATE-45-201 data in mid-2026Company's cash runway extended into Q3 2027Result DriversDMD PROGRAM COSTS - Increased R&D expenses driven by costs related to DMD programs and higher personnel expensesCOLLABORATION REVENUE DECLINE - Revenue drop attributed to completion of collaboration with VertexKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Collaboration Revenue$1.61 mlnQ3 EPS-$1.06Q3 Net Income-$44.13 mlnQ3 Income From Operations-$47.05 mlnQ3 Operating Expenses$48.67 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Entrada Therapeutics Inc is $18.50, about 62.5% above its November 5 closing price of $6.94Press Release: ID:nGNX3s0t0PFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581876067","isCrawlerRequest":true}